Star Therapeutics aims to develop drugs for rare diseases, many of which currently have no FDA-approved treatments. The company forms startups focused on particular areas of biology, and its first one, Electra Therapeutics, is going after a rare autoimmune condition that can become fatal in less than four years.
ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150!
Andrew Bott, Director of Talent Acquisition in EMEA & APAC countries at Medidata, shared his insights on hiring trends in this sector, in response to emailed questions.
By Michael Schroeder Wednesday, February 16, 2022 5:55 PM
Faculty Opinions brings together the comments and opinions of thousands of top researchers in life sciences and medicine. Combined with H1's extensive intel on healthcare providers, the acquisition expands H1's reach and opportunity to impact healthcare by bringing this data under one umbrella, H1 CEO Ariel Katz said.
By Frank Vinluan Wednesday, February 16, 2022 5:36 PM
SpliceBio will use its €50 million in financing to advance development of a gene therapy for Stargardt disease, a rare eye disorder. The biotech's technology enables the delivery of genes that are too large for the capacity of the adeno-associated viruses widely used in the delivery of genetic medicines.
By Sarah Gray Wednesday, February 16, 2022 2:21 PM
As older nurses retire and others leave the profession due to burnout, there's a very real threat of a leadership void in nursing. But making changes related to nursing culture, staffing and paths to the top can prevent that.
By Rachel Sokol Wednesday, February 16, 2022 10:54 AM
For those without a companion or person they trust to provide assistance, technology can help with some of the tasks traditionally handled by a caregiver.
Leverage the Knowledge Hub on MedCity News to elevate thought leadership and awareness and generate leads for your sales team – ONLY paying for qualified leads..
No comments